Business · 17/11/2023Updated: 10/17/2026 · 1 min read
FDA Corrects Notice on Patent Extension for ROZLYTREK INJECTION
Summary
The US Food and Drug Administration (FDA) has corrected a notice regarding the regulatory review period for patent extension of ROZLYTREK INJECTION (entrectinib), a cancer treatment, due to an error in the dosage form listed in the original document.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →